July 28, 2023 11:24 AM EDTUpdated July 28, 10:19 PM
R&D
Pharma

Sanofi, BioN­Tech cut ear­ly-stage mR­NA can­cer ther­a­py from pipeline

Paul Schloesser

Associate Editor

Sanofi and BioN­Tech scrapped de­vel­op­ment of an mR­NA ther­a­py that can be in­ject­ed in­to a tu­mor af­ter see­ing re­sults from an in­ter­im analy­sis.

Sanofi on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times